Q1 report Thursday, 24 April at 12:00 CET '25e-'27e EBITA down 3%; 6% CAGR in '24-'27e 11-9x EBITA i...
Analysguiden räknar med en fortsatt fallande vinst under Q1 2025 primärt drivet av en svagare margin...
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showi...
Redeye gives a short initial comment on the positive news that Leqembi has been approved in the EU.
Beijer Alma inleder året med tre nya förvärv och inför Q1-rapporten räknar Analysguiden med en stabi...
Ahead of Atria's Q1 report, we keep our group estimates largely intact.
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe , the...
Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint ...
Redeye comments on the updated clinical guidelines regarding the use of LITT in patients with metast...
Q1e: a solid quarter with EBITA up 11% y-o-y Higher estimates following ambitious new targets Medica...
Redeye has revised its estimates for CoinShares in anticipation of its Q1 2025 report, scheduled for...
Plejds nettoomsättning för det första kvartalet 2025 uppgick till 220,4 MSEK (159,0), en ökning med ...
Q-linea achieved its objective with five ASTar contracts during Q1, supported by a much-improved pip...
Redeye retains its positive view of Carasent following the Q1 report.
Titania AB (”Titania” eller ”Bolaget”) meddelade den 11 april år 2025 att Bolaget har tecknat ett 10...
